Atrial fibrillation nursing: assessment, interventions, and NCLEX review

Atrial fibrillation (AFib) is the most common sustained cardiac arrhythmia, affecting more than 6 million Americans and carrying a fivefold increased risk of ischemic stroke compared to patients in normal sinus rhythm. It is not simply a nuisance rhythm — it is a hemodynamic and thromboembolic threat that nurses in every setting will encounter. Med-surg patients develop new-onset AFib during sepsis and post-operatively. ICU patients with AFib in rapid ventricular response (RVR) deteriorate quickly. Outpatient AFib that goes undetected on a warfarin bridge leads to cardioembolic stroke. Understanding AFib — its mechanisms, its classifications, its treatment strategies, and its complications — is foundational nursing knowledge.

Key facts at a glance

This reference covers pathophysiology, AFib classification, rate vs rhythm control strategy, anticoagulation protocols including CHA₂DS₂-VASc scoring, cardioversion, acute nursing assessment and interventions, complications, and NCLEX-style questions. Pair it with the stroke nursing reference for cardioembolic stroke management and the EKG interpretation cheat sheet for rhythm identification.

Pathophysiology

Normal atrial conduction

Under normal conditions, the sinoatrial (SA) node fires at 60–100 times per minute, sending an organized electrical impulse across both atria simultaneously. This produces a discrete, upright P wave on the EKG and, critically, causes coordinated atrial contraction. That contraction squeezes approximately 20–30% of the final ventricular preload into the ventricle just before the mitral valve closes — a contribution called the atrial kick. In healthy hearts, the atrial kick adds roughly 15–30% to cardiac output. In patients with diastolic dysfunction, hypertrophic cardiomyopathy, or reduced ventricular compliance, the atrial kick may contribute up to 40–50% of forward flow.

Re-entry circuits and ectopic triggers

AFib is initiated by rapid, chaotic ectopic firing from multiple foci — most commonly from the ostia of the pulmonary veins as they enter the left atrium. These ectopic bursts bombard the atrial tissue at rates of 350–600 impulses per minute. The atrial tissue cannot depolarize and repolarize fast enough to follow each impulse as a coordinated wave; instead, multiple small re-entry circuits spin simultaneously across the atria in a disorganized pattern. The result is quivering atrial walls that produce no effective mechanical contraction — only a chaotic fibrillatory baseline (fine f waves) visible on EKG.

Atrial remodeling

Sustained AFib is not electrically neutral. Rapid, chaotic depolarization causes progressive structural and electrical changes in the atrial myocardium — a process called atrial remodeling. Calcium overload, oxidative stress, fibrosis, and altered ion channel expression all occur. These changes shorten atrial effective refractory periods, making the atrium increasingly vulnerable to re-initiating AFib whenever it terminates. This explains the well-known clinical observation: “AFib begets AFib.” The longer AFib persists, the harder it is to restore and maintain sinus rhythm.

AV node as a gatekeeper

The atrioventricular (AV) node receives the chaotic atrial impulses but is physiologically limited in how many it can conduct. Decremental conduction in the AV node means that impulses arriving too rapidly are blocked. The AV node passes approximately 100–170 impulses per minute to the ventricles in untreated AFib — this is “AFib with rapid ventricular response” (RVR). Importantly, even at this rate, the ventricular response is irregularly irregular because the timing of each conducted impulse is unpredictable. This produces the defining EKG pattern: no P waves, varying R-R intervals, and narrow QRS complexes (unless aberrant conduction is present).

Loss of atrial kick: hemodynamic consequences

When the atria fibrillate, coordinated atrial contraction is lost. The ventricles fill passively, and the 15–30% atrial kick contribution disappears. In patients with good ventricular function and low heart rates, this may be tolerated. In patients with:

• Diastolic dysfunction (hypertension, hypertrophic cardiomyopathy) — the ventricle is stiff and depends heavily on atrial filling; AFib causes marked CO reduction
• Rapid ventricular response — shortened diastolic filling time compounds the reduced preload
• Existing heart failure — already-compensated patients decompensate rapidly when AFib occurs

The clinical result ranges from mild palpitations and fatigue to pulmonary edema, hypotension, and cardiogenic shock, depending on the patient’s underlying cardiac reserve. See the heart failure nursing reference for the overlap between AFib and decompensated HF.

Left atrial appendage thrombus formation

With loss of coordinated atrial contraction, blood pools in the left atrial appendage (LAA) — a small, trabeculated, finger-shaped pouch off the lateral left atrium. This stagnant, turbulent flow creates ideal conditions for thrombus formation. Over 90% of cardioembolic thrombi in non-valvular AFib originate in the LAA. When a thrombus breaks loose, it enters the systemic circulation via the left ventricle. Because the carotid and cerebral arteries receive approximately 20% of cardiac output, emboli disproportionately travel to the brain — producing cardioembolic ischemic stroke. AFib accounts for approximately 15–20% of all ischemic strokes in the U.S. and for a higher proportion of severe, disabling strokes. This is the central reason why anticoagulation is the cornerstone of AFib management.

AFib classification

The ACC/AHA 2023 AFib guidelines classify AFib by duration and reversibility. Understanding these distinctions is critical because they drive treatment strategy — particularly the feasibility of cardioversion and rhythm control.

Valvular vs non-valvular AFib: An important sub-distinction affects anticoagulant choice. “Valvular AFib” historically referred to AFib in the setting of rheumatic mitral stenosis or mechanical prosthetic heart valves. These patients require warfarin — DOACs are not approved. “Non-valvular AFib” (the majority of cases) is where DOACs are preferred.

Rate control vs rhythm control

Two treatment philosophies govern AFib management. The choice between them depends on symptom burden, duration of AFib, age, cardiac function, and patient preference.

The EAST-AFNET 4 trial (2020) demonstrated that early rhythm control (initiated within 1 year of AFib diagnosis) reduced a composite of cardiovascular death, stroke, and hospitalization compared to rate control alone — representing a significant shift in guideline thinking toward earlier rhythm control in appropriate patients. The 2023 ACC/AHA guidelines now recommend early rhythm control as a Class IIa recommendation for many newly diagnosed AFib patients.

Rate control remains valid for patients with permanent AFib, those who fail or decline rhythm control, and older or high-risk patients where the benefit-risk balance of antiarrhythmics or ablation is unfavorable.

Anticoagulation

Why anticoagulation matters more than rhythm

A critical point that confuses many students: achieving sinus rhythm does not eliminate stroke risk. Patients in NSR after cardioversion can have asymptomatic AFib recurrences. The LAA may remain stunned (mechanically dysfunctional) even after sinus rhythm is restored. Anticoagulation decisions are made based on stroke risk score (CHA₂DS₂-VASc), not on whether the patient is currently in AFib.

CHA₂DS₂-VASc score

The CHA₂DS₂-VASc score quantifies annual stroke risk in non-valvular AFib and guides anticoagulation decisions. Higher scores indicate greater stroke risk and a stronger benefit from anticoagulation.

Anticoagulation thresholds (2023 ACC/AHA guidelines):

• Score ≥2 in men: oral anticoagulation recommended
• Score ≥3 in women: oral anticoagulation recommended
• Score 1 in men / Score 2 in women: anticoagulation may be considered; individualize based on bleeding risk
• Score 0 in men / Score 1 in women (female sex alone): anticoagulation not recommended

Annual stroke rates by score:

• Score 0: ~0.2% per year
• Score 1: ~0.6% per year
• Score 2: ~2.2% per year
• Score 3: ~3.2% per year
• Score 4: ~4% per year
• Score 5–6+: 6–12%+ per year

HAS-BLED — bleeding risk assessment

Before initiating anticoagulation, bleeding risk is assessed using the HAS-BLED score. A score ≥3 indicates high bleeding risk and warrants careful consideration, but it does not automatically contraindicate anticoagulation. High CHA₂DS₂-VASc scores generally outweigh bleeding risk — the goal is to identify and modify correctable bleeding risk factors (uncontrolled hypertension, excessive alcohol, concurrent NSAIDs).

HAS-BLED factors: Hypertension (uncontrolled, SBP >160), Abnormal renal or liver function (1 point each), Stroke (prior), Bleeding history or predisposition, Labile INR (time in therapeutic range <60%), Elderly (>65 years), Drugs (antiplatelets/NSAIDs) or alcohol (1 point each). Maximum 9 points.

Warfarin vs DOACs

DOACs vs warfarin — key summary: DOACs have predictable pharmacokinetics, fewer drug-food interactions, lower rates of intracranial hemorrhage, and do not require routine INR monitoring. They are the preferred choice for non-valvular AFib in most patients. Warfarin remains the standard for mechanical prosthetic heart valves, rheumatic mitral stenosis, and severe renal impairment where DOACs are contraindicated. See the nursing lab values cheat sheet for INR monitoring ranges and DVT nursing for broader anticoagulation principles in VTE.

EKG interpretation in AFib

AFib produces a distinctive and recognizable pattern on the 12-lead EKG or telemetry monitor. Students should be able to identify all four features confidently. For a broader rhythm interpretation framework, see the EKG interpretation cheat sheet.

Four hallmarks of AFib:

1. Irregularly irregular ventricular rhythm — R-R intervals vary from beat to beat with no discernible pattern. This is the most clinically important feature at the bedside (irregular pulse on palpation).
2. Absent P waves — No distinct, upright P wave precedes each QRS complex. Instead, the isoelectric baseline is replaced by chaotic, low-amplitude fibrillatory (f) waves, most visible in V1.
3. Fibrillatory baseline (f waves) — Rapid, disorganized undulations of the baseline at 350–600 per minute. Coarse f waves (larger amplitude) are more visible; fine f waves may be subtle or absent on the surface EKG.
4. Narrow QRS complex — Typically ≤120 ms, because ventricular conduction below the AV node is normal. Wide QRS complexes in AFib suggest aberrant conduction (bundle branch block, accessory pathway, or Wolff-Parkinson-White syndrome) or ventricular pacing.

AFib vs flutter: Atrial flutter produces regular, sawtooth flutter waves at approximately 300 bpm with a regular ventricular response (often 2:1, 3:1, or 4:1 block). AFib is distinguished by its irregular ventricular rate and absent discrete P waves.

Acute nursing assessment

Hemodynamic monitoring

When a patient presents with AFib or develops new-onset AFib, rapid assessment priorities include:

Immediate assessment (first 2–5 minutes):

• Vital signs: heart rate (rate and regularity), blood pressure, SpO₂, respiratory rate
• Symptoms: palpitations, dyspnea, chest pain, lightheadedness, syncope
• Level of consciousness: confusion or altered mentation suggests reduced cerebral perfusion
• If hemodynamically unstable (SBP <90 mmHg, altered consciousness, severe chest pain, signs of shock): immediate synchronized cardioversion — do not delay for anticoagulation

Signs of hemodynamic instability requiring urgent intervention:

• SBP <90 mmHg or MAP <65 mmHg
• Altered mental status
• Active chest pain (ischemic)
• Pulmonary edema (frothy sputum, severe dyspnea, SpO₂ <90% despite supplemental O₂)
• Signs of shock: mottling, cool extremities, diaphoresis

Rhythm interpretation at the bedside

The bedside assessment begins with pulse palpation. An irregularly irregular pulse — where no pattern of regularity can be detected — is the clinical hallmark of AFib. This contrasts with a regularly irregular pulse (e.g., bigeminy) or simply a fast irregular rate.

Confirm with telemetry or 12-lead EKG. Document:

• Ventricular rate (average rate on EKG strip)
• Presence or absence of P waves
• QRS width (narrow vs wide)
• Any signs of ischemia (ST changes, T-wave inversions)

Determining onset: the 48-hour rule

Establish the time of AFib onset as precisely as possible:

• Known onset <48 hours: Lower thrombus formation risk; cardioversion may proceed with anticoagulation initiated before or at the time of cardioversion
• Known onset >48 hours or unknown onset: Assume high thrombus risk; require either 3+ weeks of therapeutic anticoagulation before cardioversion OR transesophageal echocardiogram (TEE) to exclude LAA thrombus

Why 48 hours? Thrombus formation in the LAA begins after approximately 48 hours of continuous AFib. Within this window, the risk of cardioversion-related thromboembolism is low if anticoagulation is initiated promptly.

New-onset vs known AFib

Cardioversion

Cardioversion is the process of terminating AFib and restoring sinus rhythm. It can be achieved electrically or pharmacologically.

Electrical cardioversion (synchronized cardioversion)

Synchronized cardioversion delivers a direct current shock timed to the R wave (QRS complex), avoiding the T wave (the vulnerable period where unsynchronized shocks can precipitate ventricular fibrillation). It is the most reliable method for converting AFib to sinus rhythm.

Indications:

• Hemodynamically unstable AFib (immediate, regardless of anticoagulation status)
• Stable AFib where rhythm control is the chosen strategy

Pre-cardioversion checklist (stable, elective):

1. Confirm anticoagulation adequate — ≥3 weeks therapeutic warfarin (INR 2–3) or DOAC, OR TEE negative for LAA thrombus
2. Ensure IV access, cardiac monitoring, and crash cart availability
3. Obtain informed consent
4. NPO status for sedation (typically ≥4–6 hours for elective procedure)
5. Prepare for conscious sedation (propofol, midazolam, or etomidate per protocol)
6. Confirm synchronized mode is selected on the defibrillator — verify “SYNC” indicator is active
7. Apply conductive pads (anterior-posterior position preferred for AFib)
8. Administer sedation, confirm adequate sedation level before shock delivery
9. Deliver shock; confirm rhythm change on monitor

Energy levels:

• Biphasic defibrillator: 120–200 J initial dose (higher initial energy associated with higher first-shock success rates for AFib)
• Monophasic defibrillator: 200 J initial dose
• If first shock unsuccessful: escalate energy with successive attempts

Post-cardioversion nursing care:

• Monitor rhythm continuously for ≥4 hours post-procedure
• Assess vital signs every 15 minutes for 1 hour, then per protocol
• Monitor for skin burns at pad sites
• Continue anticoagulation for at least 4 weeks post-cardioversion (LAA stunning)
• Monitor for thromboembolic events (neurological changes, limb ischemia)

Nursing priority: Always verify synchronized mode before cardioversion. An unsynchronized shock during AFib (which becomes defibrillation) can precipitate VF. The sync marker should appear on the R waves on the monitor screen.

Pharmacological cardioversion

Drug-based rhythm conversion is an alternative for stable AFib of short duration (<48 hours), particularly when the patient refuses or is unsuitable for electrical cardioversion.

Rate control medications

Rate control is first-line for most patients and the sole strategy for those with permanent AFib. The target resting heart rate is <110 bpm (lenient control, evidence-based from RACE II trial) for most patients; <80 bpm (strict control) is used for symptomatic patients who remain symptomatic at rates 80–110.

Nursing interventions

Complications

Ischemic stroke and systemic embolism

The most feared complication of AFib is cardioembolic ischemic stroke. Compared to patients in sinus rhythm, patients with AFib have a fivefold increased risk of stroke. AFib-related strokes tend to be more severe and more disabling than atherothrombotic strokes — large LAA thrombi embolize to large cerebral vessels, producing large-territory infarcts with high morbidity. Approximately 15–20% of all ischemic strokes in the U.S. are attributable to AFib. Systemic embolism can also affect the mesenteric arteries (bowel ischemia), renal arteries, and peripheral arteries (acute limb ischemia). See the stroke nursing reference for acute stroke assessment and management.

Heart failure exacerbation

AFib and heart failure have a bidirectional relationship. AFib causes HF through multiple mechanisms: loss of atrial kick (reducing preload), rapid rate (shortening diastolic filling time and increasing myocardial oxygen demand), and irregular rhythm (reducing cardiac efficiency). Conversely, the structural changes of HF — elevated filling pressures, atrial dilation, and neurohormonal activation — create a substrate for AFib. When AFib develops in a compensated HF patient, decompensation can be rapid. See the heart failure nursing reference for HF management principles. Nursing assessment should include daily weights, fluid balance, lung sounds, and JVD monitoring in AFib patients with known HF.

Tachycardia-induced cardiomyopathy

Sustained rapid ventricular rates — typically >100–110 bpm for weeks to months — can cause tachycardia-induced cardiomyopathy (TIC): a reversible form of dilated cardiomyopathy resulting from chronic myocardial fatigue and energy depletion. Left ventricular ejection fraction (EF) falls, and the clinical picture resembles HF with reduced EF. The key distinguishing feature is that TIC is potentially reversible: adequate rate or rhythm control often leads to significant or complete EF recovery over weeks to months. This is why aggressive rate control in AFib with rapid response matters — it may prevent or reverse cardiomyopathy.

Hemodynamic instability and cardiogenic shock

In patients with severely compromised cardiac reserve, rapid AFib can precipitate cardiogenic shock. This is most common in patients with severe mitral stenosis (who depend almost entirely on atrial kick and controlled rate), hypertrophic obstructive cardiomyopathy (HOCM), or critical aortic stenosis. These patients require emergent cardioversion rather than pharmacological rate control, which may be inadequate or dangerously slow to achieve.

Cognitive decline and dementia

Emerging evidence suggests AFib is associated with accelerated cognitive decline and increased dementia risk, independent of clinical stroke — likely related to subclinical cerebral microemboli and reduced cerebral perfusion. This underscores the importance of anticoagulation beyond preventing clinically apparent stroke.

Patient education

Effective patient education is critical to AFib management. Poor anticoagulation adherence is the primary modifiable driver of AFib-related stroke. Key teaching points:

Anticoagulation compliance:

• Explain why anticoagulation matters: “The medication prevents blood clots from forming in your heart and traveling to your brain.”
• For warfarin patients: consistent dietary vitamin K intake (do not avoid leafy greens entirely — maintain consistent intake); attend all INR check appointments; never start or stop medications without provider knowledge (dozens of drugs affect INR); carry a medication card or wear a medical alert bracelet.
• For DOAC patients: never miss a dose; do not double-dose if a dose is missed; store medication away from heat and humidity; take rivaroxaban with the evening meal (absorption-dependent).

When to seek emergency care:

• Symptoms of stroke: sudden facial droop, arm weakness, speech difficulty, sudden severe headache, vision loss — call 911 immediately
• Severe dyspnea or sudden chest pain at rest
• Syncope or near-syncope
• Rapid or irregular heartbeat with dizziness or hemodynamic symptoms
• Signs of serious bleeding: blood in urine or stool, unusually heavy menstrual bleeding, coughing blood, vomiting blood

Rate and rhythm medications:

• Explain that heart rate medications are taken daily even when feeling well — they prevent the rate from becoming dangerously fast
• Do not stop rate-control medications abruptly (rebound tachycardia, especially with beta blockers)
• Antiarrhythmic drugs require consistent timing and should not be missed

Lifestyle modifications:

• Alcohol: even moderate alcohol consumption is a well-established AFib trigger; abstinence or strict moderation is recommended
• Sleep apnea: untreated OSA is a major, modifiable AFib risk factor; CPAP adherence reduces AFib recurrence
• Weight loss: obesity is an independent AFib risk factor; even modest weight reduction improves rhythm control outcomes
• Exercise: moderate aerobic exercise is beneficial; very high-intensity or long-duration endurance exercise can paradoxically increase AFib risk in some patients
• Hypertension control: BP below 130/80 mmHg recommended; hypertension is the most common modifiable AFib risk factor

Activity:

• Most AFib patients can maintain normal activity with rate control; palpitations during exertion should be reported
• Patients on anticoagulation should minimize contact sports and activities with fall risk; report all falls and injuries

NCLEX-style questions

Question 1

A nurse is caring for a patient with known atrial fibrillation who has not taken warfarin for three weeks. The patient now presents for elective electrical cardioversion. The physician wishes to proceed with cardioversion today. What is the nurse’s priority action?

A. Prepare the defibrillator in asynchronous mode B. Notify the physician that a TEE or 3-week therapeutic anticoagulation is required before elective cardioversion C. Administer IV metoprolol to slow the rate before cardioversion D. Obtain informed consent and proceed with cardioversion as ordered

Question 2

A nurse is assessing a 72-year-old male patient with newly diagnosed AFib. He has a history of hypertension, type 2 diabetes, and a prior ischemic stroke 2 years ago. What is his CHA₂DS₂-VASc score, and what does this indicate about anticoagulation?

A. Score 3 — anticoagulation is optional B. Score 5 — anticoagulation is strongly recommended C. Score 4 — anticoagulation decision should be deferred to cardiology D. Score 2 — anticoagulation is not indicated in males with score <2

Question 3

A nurse is preparing to administer IV diltiazem to a patient in AFib with rapid ventricular response (rate 158 bpm). Review of the medical record shows the patient received IV metoprolol 5 mg 20 minutes ago and the rate only decreased to 158. What should the nurse do?

A. Administer the diltiazem as ordered — the rate remains elevated and rate control is the priority B. Hold the diltiazem and notify the provider — concurrent IV beta blocker and IV CCB administration carries severe hemodynamic risk C. Administer diltiazem at half the ordered dose to minimize risk D. Administer diltiazem only if the patient’s blood pressure is above 120/80 mmHg

Question 4

A patient on digoxin for AFib rate control develops nausea, vomiting, and sees yellow-green halos around lights. Their potassium is 3.0 mEq/L. What is the nurse’s priority action?

A. Administer the next scheduled dose of digoxin and monitor symptoms B. Hold digoxin, notify the provider, monitor telemetry, and prepare to address the hypokalemia C. Administer IV potassium at 20 mEq/hour immediately D. Request a 12-lead EKG and proceed with scheduled digoxin dose if no arrhythmia is visible

Question 5

Which patient with atrial fibrillation is the best candidate for a rate-control rather than rhythm-control strategy?

A. A 45-year-old with paroxysmal AFib, symptomatic palpitations, and preserved EF B. A 68-year-old with permanent AFib, no symptoms at a rate of 85 bpm C. A 55-year-old with new-onset AFib found to be driving heart failure with reduced EF D. A 40-year-old competitive athlete with first-episode AFib

Question 6

A patient with AFib is being discharged on apixaban (Eliquis) 5 mg twice daily for stroke prevention. Which patient statement indicates that additional teaching is needed?

A. “I should take this medication every 12 hours, even if I feel fine.” B. “I don’t need to get blood tests every month like I did on warfarin.” C. “If I miss a dose, I should take two doses the next morning to make up for it.” D. “I should tell my dentist I’m on a blood thinner before any procedures.”

References

• January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation. J Am Coll Cardiol. 2019;74(1):104–132.
• Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS guideline for diagnosis and management of atrial fibrillation. J Am Coll Cardiol. 2024;83(1):109–279.
• Hindricks G, Potpara T, Dagres N, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation. Eur Heart J. 2021;42(5):373–498.
• Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest. 2010;137(2):263–272.
• Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation. Chest. 2010;138(5):1093–1100.
• Van Gelder IC, Rienstra M, Bunting KV, et al. 2024 ESC guidelines for the management of atrial fibrillation (update). Eur Heart J. 2024.
• Zimetbaum P. Atrial fibrillation. Ann Intern Med. 2017;166(5):ITC33–ITC48.
• StatPearls: Atrial fibrillation. National Center for Biotechnology Information (NCBI). Updated 2024.
• American Heart Association. Understand your risk for atrial fibrillation. AHA Scientific Statement, 2023.